Browse > Article

Intraoperative Radiation Therapy for Unresectable Pancreatic Cancer  

Lee, Nam-Kwon (Department of Radiation Oncology, Korea University College of Medicine)
Kim, Chul-Yong (Department of Radiation Oncology, Korea University College of Medicine)
Park, Young-Je (Department of Radiation Oncology, Korea University College of Medicine)
Lee, Suk (Department of Radiation Oncology, Korea University College of Medicine)
Publication Information
Annals of Hepato-Biliary-Pancreatic Surgery / v.14, no.4, 2010 , pp. 254-261 More about this Journal
Abstract
Purpose: We wanted to evaluate the clinical effectiveness of intraoperative radiation therapy (IORT) in combination with external beam radiation therapy (EBRT) for treating unresectable or metastatic pancreatic cancer. Methods: From August 1993 to July 2007, 28 patients with unresectable or metastatic pancreatic cancer received IORT (median: 20 Gy) combined with or without EBRT (median: 50.4 Gy). Eighteen patients were treated with IORT followed by EBRT, and 10 patients were treated by IORT alone. Eighteen patients underwent explolaparotomy and 10 patients underwent bypass surgery. Results: The 1-year overall survival rate (OS) and the median survival time of all 28 patients were 21.4% and 7.5 months, respectively. The 1-year OS and median survival time for the clinical stage III patients were 33.3% and 10.2 months, respectively, and they were 7.7% and 5.1 months for the clinical stage IV patients, respectively (p=0.007). Univariate analyses revealed that the stage, chemotherapy and tumor volume were the significant prognostic factors for OS. The patients treated with IORT combined with EBRT had a more favorable 1-year local control rate than that of those patients treated with IORT alone (88.9% vs. 50.0, respectively, p=0.009). But the significant improvement in local control did not translate into a survival benefit. The addition of EBRT was an independent prognostic factor for improving the local control rate. The operative mortality was 0%. Conclusion: IORT combined with EBRT is considered to be effective in achieving local control and palliation for patients with unresectable or metastatic pancreatic cancer. Further, IORT seems to be safe and it does not increase the mortality or the incidence of surgical wound infection.
Keywords
Pancreatic cancer; Radiation therapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538-4544.   DOI   ScienceOn
2 Mohiuddin M, Regine WF, Stevens J, et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995;13:2764-2768.   DOI
3 Ogawa K, Karasawa K, Ito Y, et al. Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print].
4 Bruera E, Hui D. Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. J Clin Oncol 2010;28:4013-4017.   DOI   ScienceOn
5 World Health Organization. National Cancer Control Programmes: policies and managerial guidelines. http://www. who.int/cancer/palliative/definition/en/.
6 Ministry for Heath, Welfare and Family Affairs. Annual Report of cancer incidence (2007) and survival (1993-2007) in Korea. 2009.
7 Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007;110: 738-744.   DOI   ScienceOn
8 Evans D, Abbruzzese J, Willett C. Cancer of the pancreas. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
9 Willett CG, Czito BG, Bendell JC. Cancer of the Pancreas. In: Perez CA, Brady LW, editors. Principles and Practice of Radiation oncology. 5th ed. Philadelphia, PA: Lippincott Co.; 2009.1336-1346.
10 Kruse EJ. Palliation in pancreatic cancer. Surg Clin North Am 2010;90:355-364.   DOI   ScienceOn
11 Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973;32:1341-1345.   DOI   ScienceOn
12 Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage 1988;3:199-205.   DOI   ScienceOn
13 Ryu MR, Yoon SC, Kim YS, Chung SM. The results of palliative radiation therapy in patients with unresectable advanced pancreatic cancer. J Korean Soc Ther Radiol Oncol 2006;24:243-247.   과학기술학회마을
14 Ruano-Ravina A, Almazan Ortega R, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 2008;87:318-325.   DOI   ScienceOn
15 Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.   DOI   ScienceOn
16 Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867.
17 Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads＋5-fluorouracil), and high dose radiation ＋5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710.   DOI   ScienceOn
18 Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98-104.   DOI   ScienceOn
19 Kim TY. Chemotherapy for advanced pancreatic cancer. Korean J Hepatobiliary Pancreat Surg 2004;8:147-151.
20 Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19: 1592-1599.   DOI   ScienceOn
21 Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008:26 (Suppl; abstr 4506)
22 Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-1256.   DOI   ScienceOn
23 Sindelar WF, Kinsella TJ. Normal tissue tolerance to intraoperative radiotherapy. Surg Oncol Clin N Am 2003;12: 925-942.   DOI   ScienceOn